Madrigal Pharmaceuticals Wins Accelerated Approval for Rezdiffra From FDA

By Denny Jacob

Madrigal Pharmaceuticals' Rezdiffra was granted accelerated approval from the Food and Drug Administration.

The clinical-stage biopharmaceutical company noted the approval for Rezdiffra, in conjunction with diet and exercise, was to treat adults with noncirrhotic nonalcoholic steatohepatitis with moderate to advanced liver fibrosis.

Madrigal said Rezdiffra is expected to be available to patients in the U.S. in April and will be distributed through a limited specialty pharmacy network.

Write to Denny Jacob at [e-mail]

(END) Dow Jones Newswires

03-14-24 1705ET